Association between renin-angiotensin-aldosterone system inhibitors, clinical outcomes in patients with COVID-19
What The Study Did: Researchers compared mortality and severe adverse events in this systematic review and meta-analysis of 52 studies that evaluated clinical outcomes among nearly 102,000 patients with COVID-19 who did and didn’t receive angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).
Authors: Vassilios S. Vassiliou, M.B.B.S., Ph.D., of the University of East Anglia in Norwich, United Kingdom is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor’s Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Media Relations